Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma

Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approxim...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Clin Cancer Res
Autors principals: Liu, Ziyu, Lin, Yan, Zhang, Jinyan, Zhang, Yumei, Li, Yongqiang, Liu, Zhihui, Li, Qian, Luo, Ming, Liang, Rong, Ye, Jiazhou
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6827249/
https://ncbi.nlm.nih.gov/pubmed/31684985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1412-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars